GlassScriptPhysician profile
Jealena Reesor
NPI 1124308341
$10,096.37
in general payments reported to CMS, 2019-2025
33 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,185 · 2022: $2,015 · 2023: $2,064 · 2024: $2,498 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,809 · Education: $87.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,808.50 |
| Education | $87.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,540.11 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,148.84 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $872.54 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $671.31 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $545.39 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $480.51 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $365.91 | 2021-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $353.94 | 2022-2023 | Stelara |
| Ardelyx, INC. | $310.01 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $284.11 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $241.42 | 2025 | Rezdiffra |
| Qol Medical, LLC | $210.23 | 2021-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $190.68 | 2021-2022 | |
| Celgene Corporation | $122.09 | 2021-2024 | Zeposia |
| Evoke Pharma, INC. | $91.62 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $81.87 | 2022-2025 | Ocaliva |
| Daiichi Sankyo INC. | $72.92 | 2021-2024 | Injectafer |
| Medtronic, INC. | $61.85 | 2022 | |
| Redhill Biopharma INC. | $56.62 | 2021-2023 | Talicia |
| Gilead Sciences, INC. | $47.94 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.88 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $47.02 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $45.57 | 2024 | Givlaari |
| Braintree Laboratories, INC. | $39.63 | 2023-2025 | Suflave |
| Aimmune Therapeutics, INC. | $35.24 | 2023-2025 | Zenpep |
| Celltrion USA INC. | $26.87 | 2024 | Zymfentra |
| Tersera Therapeutics LLC | $18.35 | 2021 | |
| Pfizer INC. | $17.02 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.11 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.04 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.09 | 2025 | Rebyota |
| Merck Sharp & Dohme LLC | $13.38 | 2024 | Dificid |
| Organon LLC | $11.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jealena Reesor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.